Guggenheim Maintains Buy on Jade Biosciences, Lowers Price Target to $41
Jade Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Jade Biosciences Q3 EPS $(0.42) Beats $(0.71) Estimate
Jade Biosciences to Participate in Upcoming Conferences
BTIG Reiterates Buy on Jade Biosciences, Maintains $77 Price Target
Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026
Wedbush Reiterates Outperform on Jade Biosciences, Maintains $47 Price Target
HC Wainwright & Co. Reiterates Buy on Jade Biosciences, Maintains $55 Price Target
Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis - Slideshow
Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis Transcript
Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
Jade Biosciences, Inc. (JBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Jade Biosciences: Duration Is The Real Product
Wedbush Maintains Outperform on Jade Biosciences, Raises Price Target to $47
Jade Biosciences Q2 EPS $(0.76) Misses $(0.64) Estimate
Jade Biosciences Enters Exclusive Worldwide License Agreement With Paragon Therapeutics; To Pay Up To $22M In Milestone Payments To Paragon; To Pay Paragon Low To Mid-Single-Digit Percentage Royalties On Net Sales Of Licensed Products; Paragon Barred From New Campaigns Targeting Licensed Target For At Least Five Years
Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market?
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
UBS Initiates Coverage On Jade Biosciences with Buy Rating, Announces Price Target of $45
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.